Shelter Pharma Limited has successfully converted warrants into equity shares, marking a significant milestone in its capital structure enhancement. The pharmaceutical company's board of directors approved the conversion of 2,79,000 warrants into 1,14,000 equity shares during their meeting held on May 01, 2026.

Warrant Conversion Details

The conversion process involved three non-promoter investors who exercised their option to convert warrants into equity shares. The board approved the allotment of 1,14,000 equity shares of face value Rs. 10 each, fully paid, upon receipt of the remaining exercise price.

Investor Participation

Three non-promoter investors participated in the warrant conversion process, with varying levels of conversion from their allocated warrants.

Capital Structure Impact

The warrant conversion has resulted in an expansion of the company's equity base. The paid-up equity share capital increased from Rs. 166117920 consisting of 16611792 equity shares to Rs. 167257920 consisting of 16725792 equity shares, all with face value of Rs. 10 each.

The newly allotted equity shares rank pari-passu with existing equity shares of the company in all respects. The allotment was made for cash upon receipt of the remaining exercise price of Rs. 31.6875 per warrant, representing 75% of the original warrant issue price of Rs. 42.25 per warrant.

Background and Regulatory Compliance

The warrant conversion follows the company's earlier disclosure dated August 06, 2025, regarding the allotment of 88,08,000 convertible equity warrants. The original warrant allotment was approved by shareholders at the Extra Ordinary General Meeting held on July 23, 2025, and received in-principle approval from BSE Limited through their letter dated July 22, 2025.

The warrants were issued at Rs. 42.25 each, including a premium of Rs. 32.25 per warrant, with initial subscription money collected at 25% of the issue price. The company will apply for listing and trading approval from the stock exchange for the newly issued equity shares in due course.

Meeting Details

The board meeting commenced at 12:00 P.M. and concluded at 12:15 P.M. on May 01, 2026. The decision was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Shelter Pharma Limited has announced the commencement of product dispatch operations to Sudan, marking another milestone in its international expansion strategy. The pharmaceutical company disclosed this development under SEBI Regulation 30 on April 16, 2026.

Export Operations to Sudan

The company has begun loading stocks for shipment to Sudan, which includes its flagship product "Allvitamin", a daily multivitamin supplement. This dispatch forms part of Shelter Pharma Limited's regular export supply operations to African markets, demonstrating the company's established presence in the region.

Strategic Market Positioning

This export initiative reflects Shelter Pharma Limited's continued commitment to strengthening its global presence and maintaining consistent supply relationships in international markets. The company's focus on African markets demonstrates its strategic approach to geographic diversification and market expansion.

Business Impact

The export operations contribute to the company's revenue diversification strategy and support business growth through international market penetration. The regular supply arrangements with African markets indicate established trade relationships and operational consistency in the company's export business.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency in the company's operational developments for stakeholders and investors.